CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.
Press: Article in Pharmaceutical Online
CMAC’s John Mulgrew has published an article in Pharmaceutical Online about the REMEDIES project and CMAC’s contribution to it. .... more
Prof Litster wins Geldart Medal from IChemE
CMAC’s Prof Jim Litster (Sheffield) has won the Geldart Medal from IChemE.
The medal founded in 2014, is awarded biennially to one or more individuals who have made a significant recent contribution to research in particle technology. This is recognised through scientific advancements widely acknowledged within the community and high impact findings recognised outside the particle technology community.
CMAC in Chemistry World
CMAC has featured in the April 3rd edition of Chemistry World. The article "The Flow Revolution" can be read here though you will need a subscription to RSC in order to access it..... more